Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kalvista Pharmaceuticals Inc
(NQ:
KALV
)
12.96
+0.33 (+2.61%)
Streaming Delayed Price
Updated: 3:46 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kalvista Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
Next >
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
February 16, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 15, 2024
Via
Benzinga
KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants
February 15, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Insiders Buying Dorian LPG And 2 Other Stocks
January 17, 2024
Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
KalVista Pharma: Q2 Earnings Insights
December 07, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 14, 2024
Via
Benzinga
KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
February 14, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
February 14, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday?
February 13, 2024
Results from KalVista Pharmaceuticals' Phase 3 KONFIDENT trial. Sebetralstat, an oral on-demand therapy, shows efficacy for hereditary angioedema.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 13, 2024
Via
Benzinga
KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema
February 13, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Insiders Buying Monro And 3 Other Stocks
February 09, 2024
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying
February 02, 2024
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
January 30, 2024
Although U.S. stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
January 22, 2024
Via
Benzinga
$230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying
January 22, 2024
Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
Via
Benzinga
Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks
January 11, 2024
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.
Via
Benzinga
$6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
January 08, 2024
Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades.
Via
Benzinga
Around $2.4M Bet On HighPeak Energy? Check Out These 4 Stocks Insiders Are Buying
January 02, 2024
Although U.S. stocks closed lower on Friday, there were a few notable insider trades.
Via
Benzinga
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology
December 20, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024
December 07, 2023
KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
December 07, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
3 Micro-Cap Stocks That Could Be Moonshots
November 14, 2023
If you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields.
Via
InvestorPlace
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
November 14, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone Achieved
November 13, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
November 07, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 03, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
November 02, 2023
From
KalVista Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.